68Ga-FAPI PET/CT in Malignant Tumors

Recruiting N/A Interventional Study
Fibroblast Activation Protein Inhibitor PET/CT Malignant Neoplasm
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 88
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
500 (estimated)
Sponsor
Zhongnan Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP in…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Volunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor Exclusion Criteria: Female patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs…
Contacts

Yong He, MD, PhD

+86-27-67812698

vincentheyong@163.com

CONTACT